Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dependovirus | 7 | 2022 | 750 | 2.010 |
Why?
|
| Genetic Vectors | 7 | 2022 | 917 | 1.650 |
Why?
|
| MicroRNAs | 5 | 2021 | 710 | 0.780 |
Why?
|
| Genetic Therapy | 6 | 2023 | 838 | 0.760 |
Why?
|
| Alphavirus | 1 | 2021 | 3 | 0.680 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 9 | 0.670 |
Why?
|
| Oncolytic Viruses | 1 | 2021 | 10 | 0.670 |
Why?
|
| Exosomes | 1 | 2021 | 53 | 0.670 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 23 | 0.650 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 97 | 0.600 |
Why?
|
| Transduction, Genetic | 1 | 2021 | 243 | 0.600 |
Why?
|
| Antigen Presentation | 1 | 2021 | 238 | 0.590 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.530 |
Why?
|
| Gene Transfer Techniques | 5 | 2023 | 325 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.520 |
Why?
|
| Immunity, Innate | 2 | 2021 | 819 | 0.460 |
Why?
|
| Pandemics | 1 | 2020 | 672 | 0.460 |
Why?
|
| Transgenes | 2 | 2022 | 204 | 0.330 |
Why?
|
| Neoplasms | 1 | 2021 | 1365 | 0.320 |
Why?
|
| Animals | 10 | 2023 | 21292 | 0.220 |
Why?
|
| Antigen-Presenting Cells | 2 | 2021 | 178 | 0.200 |
Why?
|
| Oligonucleotides | 2 | 2023 | 229 | 0.190 |
Why?
|
| Myostatin | 1 | 2020 | 20 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2021 | 86 | 0.160 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 103 | 0.160 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 36 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2020 | 197 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 583 | 0.150 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 39 | 0.150 |
Why?
|
| Ovalbumin | 1 | 2019 | 108 | 0.150 |
Why?
|
| Mice | 6 | 2023 | 11088 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2021 | 271 | 0.140 |
Why?
|
| Binding Sites | 1 | 2021 | 920 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 70 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 170 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2019 | 134 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 210 | 0.140 |
Why?
|
| RNA Polymerase III | 1 | 2018 | 10 | 0.140 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2018 | 22 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 980 | 0.130 |
Why?
|
| Humans | 9 | 2023 | 64954 | 0.130 |
Why?
|
| Follistatin-Related Proteins | 1 | 2017 | 22 | 0.130 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 49 | 0.130 |
Why?
|
| Glioma | 1 | 2018 | 101 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3469 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 205 | 0.120 |
Why?
|
| Wound Healing | 1 | 2017 | 193 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 521 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 907 | 0.100 |
Why?
|
| Mice, Inbred NOD | 3 | 2019 | 526 | 0.090 |
Why?
|
| Mice, SCID | 2 | 2019 | 518 | 0.070 |
Why?
|
| Female | 3 | 2021 | 33927 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 2152 | 0.050 |
Why?
|
| Male | 2 | 2021 | 30953 | 0.050 |
Why?
|
| Muscular Diseases | 1 | 2020 | 50 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 321 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 394 | 0.040 |
Why?
|
| Vaccines | 1 | 2021 | 96 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 65 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 242 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2019 | 110 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 297 | 0.040 |
Why?
|
| Myocardium | 1 | 2020 | 301 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 169 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2020 | 222 | 0.030 |
Why?
|
| Muscles | 1 | 2019 | 179 | 0.030 |
Why?
|
| RNAi Therapeutics | 1 | 2018 | 12 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 962 | 0.030 |
Why?
|
| Genes, Switch | 1 | 2017 | 6 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2018 | 81 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 277 | 0.030 |
Why?
|
| Oncogenes | 1 | 2018 | 70 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 128 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 203 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 843 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 752 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 610 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2019 | 531 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 166 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 295 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 615 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 770 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 260 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 951 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 673 | 0.030 |
Why?
|
| RNA Interference | 1 | 2018 | 643 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1564 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2281 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 1639 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1036 | 0.020 |
Why?
|